source
- Merck’s eye-drug matches Lucentis in vision improvement but raises safety concernsMerck reported results from its Phase 2b/3 BRUNELLO trial of remigromig, a Wnt-pathway agonist for diabetic macular edema. The drug achieved non-inferior improvement in best-corrected visual acuit…
- Basecamp Research secures $140 million Series C to accelerate AI-designed drug pipelineBasecamp Research announced closing a $140 million Series C financing round to further develop its AI-driven drug discovery platform. The round was led by venture firm S32 and included participati…